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Recent studies demonstrate an increased risk of second primary malignancies (SPMs) in patients with
multiple myeloma (MM) receiving maintenance lenalidomide after autologous stem cell transplantation
(ASCT). We explored the possibility of other risk factors driving post-ASCT SPMs in patients with MM through
analysis of our large transplantation database in conjunction with our Long-Term Follow-Up Program. We
conducted a retrospective cohort study of 841 consecutive patients with MM who underwent ASCT at City of
Hope between 1989 and 2009, as well as a nested case-control analysis evaluating the role of all therapeutic
exposures before, during, and after ASCT. Median duration of follow-up for the entire cohort was 3.4 years
(range, 0.3-19.9 years). Sixty cases with a total of 70 SPMs were identiﬁed. The overall cumulative incidence of
SPMs was 7.4% at 5 years and 15.9% at 10 years when nonmelanoma skin cancers (NMSCs) were included and
5.3% at 5 years and 11.2% at 10 years when NMSCs were excluded. Multivariate analysis of the entire cohort
revealed associations of both older age (55 years; relative risk, 2.3; P < .004) and race (non-Hispanic white;
relative risk, 2.4; P ¼ .01) with an increased risk of SPM. Furthermore, thalidomide exposure demonstrated
a trend toward increased risk (odds ratio, 3.5; P ¼ .15); however, an insufﬁcient number of patients were
treated with lenalidomide to allow us to accurately assess the risk of this agent. Exclusion of NMSCs retained
the association with these variables but was accompanied by loss of statistical signiﬁcance. This large single-
institution analysis identiﬁed associations between race and older age and increased risk of developing SPM.
The trend toward increased risk with thalidomide exposure suggests a class effect from immunomodulatory
drugs that might not be restricted to lenalidomide.
 2013 American Society for Blood and Marrow Transplantation.INTRODUCTION
High-dose therapy with autologous stem cell trans-
plantation (ASCT) has been considered a standard of care for
patients with multiple myeloma (MM) since the IFM2004
trial demonstrated an improved survival rate for patients
treated with high-dose chemotherapy compared with
conventional chemotherapy [1,2]. Over the ensuing years,
MM has become a leading indication for ASCT in the United
States. High-dose therapy in conjunction with induction and
maintenance therapy with novel agents such as thalidomide,
lenalidomide, and bortezomib has further improved survival
in patients with MM. Ten-year survival in younger patients is
approaching 50% [3].
As MM survival improves, the long-term impacts of novel
therapies and ASCT are coming under investigation. Potential
long-term adverse effects have led to a paradigm of intensive
treatment for cytogenetically deﬁned high-risk patients and
toxicity-minimizing treatment in lower-risk patients. This
approach may involve a choice of induction regimens and/or
optimization of consolidation andmaintenance therapy post-
ASCT. Thalidomidemaintenance has demonstrated improved
progression-free survival in several randomized trials, as welledgments on page 264.
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mide,which has amore favorable toxicity proﬁlewith respect
to peripheral neuropathy and sedation, has been used for
maintenance therapy inmore recent trials. Three randomized
trials have reported a progression-free survival advantage for
lenalidomide maintenance either with or without ASCT, and
one group also reported an overall survival beneﬁt [6-8].
However, both the IFM2005 trial [6] and the CALGB100104
trial [7] of maintenance lenalidomide versus observation
post-ASCT reported an increased incidence of second primary
malignancies (SPMs) in themaintenance arm compared with
the control arm (8% vs 3%-4%).
The factors driving post-ASCT SPMs in patients with MM
remain unclear, however, and lenalidomide may not be the
sole putative contributor. The cause is likely multifactorial,
involving host factors in addition to treatment. In fact, large
epidemiologic studies have demonstrated that patients with
monoclonal gammopathy of undetermined signiﬁcance are at
increased risk for additionalmalignancies [9]. Previous studies
from our institution and others have shown an increased risk
of SPMs after ASCT in patients with lymphoid neoplasms,
suggesting that treatment-related factors independent of
immunomodulatory drugs may also drive the risk of therapy-
relatedmalignancy [10-12]. InMM, the riskof post-ASCTSPMs
may be mediated in part by the alkylator agents commonly
used to treat MM before the advent of novel agents. A retro-
spective study evaluating exposure to alkylators before
ASCT for MM demonstrated an increased incidence ofTransplantation.
Table 1
Demographic and Clinical Characteristics of the Cohort
Characteristic Entire Cohort Patients with
SPMs Including
NMSCs*
Patients with
SPMs Excluding
NMSCsy
Number of patients 841 60 42
Sex, n (%)
Female 330 (39) 17 (28) 12 (29)
Male 511 (61) 43 (72) 30 (71)
Race/ethnicity, n (%)
Non-Hispanic
Caucasian
511 (61) 49 (82) 31 (74)
Hispanic 151 (18) 5 (8) 5 (12)
African American 107 (13) 4 (7) 4 (9)
Other 72 (9) 2 (3) 2 (5)
Age at ASCT, y
Median (range) 56 (18-77) 59 (32-77) 56 (32-69)
Mean (standard
deviation)
55 (8.9) 57 (9.4) 55 (9.5)
Age at diagnosis of
MM, y
Median (range) 55 (18-76) 57 (31-76) 54 (31-68)
Mean (standard
deviation)
54 (8.9) 55 (9.4) 53 (9.3)
Year of diagnosis
of MM, n (%)
1983-1999 206 (24) 30 (50) 25 (60)
2000-2004 301 (36) 20 (33) 11 (26)
2005-2009 334 (40) 10 (17) 6 (14)
Year of ASCT, n (%)
1989-1999 133 (16) 22 (37) 18 (43)
2000-2004 278 (33) 22 (37) 15 (36)
2005-2009 430 (51) 16 (27) 9 (21)
Stem cell source, n (%)
Peripheral blood 841 (100) 60 (100) 42 (100)
Disease status at
ASCT, n (%)
Partial remission 578 (69) 44 (73) 33 (79)
Stable disease 115 (14) 9 (15) 4 (9)
Complete remission 111 (13) 7 (12) 5 (12)
Progressive disease 31 (4) 0 (0) 0 (0)
Unknown 6 (0.7) 0 (0) 0 (0)
Transplantation
type, n (%)
Single autologous 527 (63) 32 (53) 22 (55)
Tandem autologous 229 (27) 18 (30) 12 (29)
Multiple 85 (10) 10 (17) 7 (17)
* Including non-melanoma skin cancers.
y Excluding non-melanoma skin cancers.
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chemotherapy exposure [13]. To better address the relation-
ship of SPMs to treatment and demographic variables, we
conducted an analysis of patients undergoing ASCT for MM at
City of Hope over the past 20 years.
PATIENTS AND METHODS
The Long-Term Follow-Up Program supports complete follow-up of all
patients undergoing ASCT at City of Hope. The protocol was approved by the
City of Hope Institutional Review Board and conforms to the standards
speciﬁed in the Declaration of Helsinki. A total of 869 patients underwent
ASCT for MM at City of Hope between 1989 and 2009. Of these, 28 patients
refused to participate in the Long-Term Follow-Up Program. This analysis
includes the remaining 841 patients (participation rate, 96.8%).
Demographic Data and Clinical Characteristics
Demographic data (date of birth, sex, and race/ethnicity) and clinical
characteristics (primary diagnosis, date of diagnosis, date of ASCT, disease
status at ASCT, conditioning regimen, and stem cell source) were obtained
from the ASCT database.
SPMs and Vital Status Information
Information regarding SPMs and vital status of the cohort was ascer-
tained as of December 31, 2010. To ensure complete ascertainment of SPMs,
institutional long-term follow-up data were combined with data from the
California Cancer Registry and National Death Index Plus Program. For
institutional long-term follow-up, medical records served as the primary
source of data. If the date of the last medical visit at City of Hope was not
recent, or if there were gaps in patients’ history within the window of
interest, a standard protocol was used to contact physicians outside City of
Hope to obtain relevant details for the period of interest. If the physicianwas
not available or able to provide recent information, the patient was con-
tacted to obtain this information. Patient vital status was obtained through
the following resources: National Death Index Plus, Social Security Death
Index, medical records, and institutional long-term follow-up efforts.
Cohort Analysis
The cumulative incidence of SPMs was estimated by taking into
consideration death from other causes as a competing risk [14]. Person-
years at risk were computed from the date of ASCT to the date of death,
date of SPM, or date of censoring (December 31, 2010, for those still alive
without SPM), whichever occurred ﬁrst. For multiple occurrences of non-
melanoma skin cancers ([NMSCs] including basal cell carcinoma [BCC] and
squamous cell carcinoma [SCC]), the date of ﬁrst occurrence was considered
the onset date. The proportional hazard regression method was used to
examine the associations between demographic data (sex and race) and
clinical characteristics (age at diagnosis of MM and year of ASCT) and the
development of SPMs, measured by hazard ratios (HRs) and corresponding
95% conﬁdence intervals (CIs) and P values [15]. The analyses were con-
ducted both with the entire cohort and with the exclusion of NMSCs.
Nested Case-Control Analysis
A nested case-control study was also conducted to examine the role of
pre-ASCT, peri-ASCT, and post-ASCT therapeutic exposures associated with
SPMs. Controls were patients with MM without post-ASCT SPMs, matched
to index case by year of ASCT (5 years). In addition, each control was
required to have longer post-ASCT follow-up than its associated case. The
conditional logistic regression method was used for the case-control anal-
ysis; odds ratios (ORs) and their corresponding 95% CIs and P values are
presented. Statistical analyses were performed using SAS 9.2 (SAS Institute,
Cary, NC). All P values are 2-sided.
RESULTS
Cohort Study
Patient demographic and clinical characteristics are
detailed in Table 1. The median duration of follow-up was
3.4 years (range, 0.3-19.9 years). The median age at diagnosis
of MMwas 55 years (range,18-76 years) and that at ASCTwas
56 years (range, 18-77 years). There was a male predomi-
nance (61%), and the racial/ethnic distribution was 61% non-
Hispanic white, 18% Hispanic, and 13% African American.
Almost two-thirds (62%) of the patients received a single
ASCT, 27% received tandem ASCT, and the remaining 11%
received multiple ASCTs (72 of whom received an allogeneic
transplantion after an ASCT).As of December 31, 2010, 60 patients had developed
a total of 70 SPMs. The SPMs included 27 NMSCs (13 BCC and
14 SCC), 4 melanomas, 9 therapy-related MDS/acute
myelogenous leukemias (t-MDS/AML), 5 prostate cancers, 4
colorectal cancers, 4 oropharyngeal cancers, 3 breast cancers,
2 acute lymphoblastic leukemias, 2 bladder cancers, and 1
case each of adrenocortical carcinoma, esophageal carci-
noma, gastric carcinoma, germ cell tumor, non-Hodgkin
lymphoma, pancreatic carcinoma, renal cell carcinoma,
thyroid cancer, uterine cancer, and site unknown. The overall
cumulative incidence was 7.4% at 5 years and 15.9% at 10
years (Figure 1). After excluding NMSCs, the overall cumu-
lative incidence was 5.3% at 5 years and 11.2% at 10 years
(Figure 1). The cumulative incidence of t-MDS/AML for the
entire cohort was 1.0% at 5 years and 2.0% at 10 years,
whereas for patients with solid tumors (excluding NMSCs), it
was 3.7% at 5 years and 8.2% at 10 years (Figure 1).Cohort Risk Factor Analysis
Table 2 presents the results of the multivariate analysis
including and excluding NMSCs. With the inclusion of
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non-Hispanic white race (relative risk [RR], 2.4; 95% CI, 1.2-
4.6: P ¼ .01) and older age (55 years) at diagnosis of MM
(RR, 2.3; 95% CI, 1.3-4.1; P ¼ .004) were associated with an
increased risk of developing SPMs, after adjustment for sex
and year of ASCT. However, after excluding NMSCs, the
magnitude of these associations was mitigated, and the
associations became nonsigniﬁcant.Case-Control Study
Table 3 presents demographic characteristics and thera-
peutic exposures for the cases (including and excluding
NMSCs) and matched controls. Table 4 summarizes results
for the variables that were retained in the multivariate
analysis of the case-control study. Similar to the cohort
analysis results, older age at diagnosis of MM and non-
Hispanic white ethnicity were associated with an increased
risk of developing SPMs after ASCT when NMSCs were
included. Individually, none of the therapeutic agents used in
the pre-ASCT, peri-ASCT, or post-ASCT periods was associ-
ated with development of SPMs after ASCT (Table 3).
However, exposure to thalidomide either pre-ASCT or post-
ASCT demonstrated a trend toward positive association
when NMSCs were included in the analysis (OR, 3.5; 95% CI,
0.6-19.4; P ¼ .15) (Table 4). Only 6 patients (3 cases and 3
controls) were exposed to lenalidomide before the devel-
opment of SPMs, and exposure to this agent was not asso-
ciated with an increased risk of SPMs (OR, 1.0; 95% CI,
0.14-7.1). Data on total CD34þ cell yields were available for 55
of the 60 cases and for 52 of the 60 controls. Themean CD34þ
cell yield was slightly lower in the cases compared with the
controls (7.8  106 cells vs 9.5  106 cells; P ¼ .08). The
median CD34þ cell yield was 7.4106 cells (range,1.8-24.5
106) for cases and 8.6  106 cells (range, 1.7-32.4  106 cells)
for controls. Five of the cases had poor-risk cytogenetics
(deletion 13 by metaphase karytoyping or deletion 17p by
FISH), as did 5 controls (deletion 13 by metaphase kar-
yotyping or deletion 17p, t[14,16]). Similar to the cohort
analysis results, exclusion of the NMSCs resulted in some
mitigation of themagnitude of risk with these variables, with
the associations no longer statistically signiﬁcant.0
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Figure 1. Cumulative incidence of SPMs in the cohort. The cumulative inci-
dence of SPMs (%) from the date of ASCT (years) was calculated using death
from other causes as a competing risk. Number at risk was 841 at ASCT (time
0), 378 at 5 years post-ASCT, and 82 at 10 years post-ASCT. The solid black line
represents overall cumulative incidence (all types of SPMs), the gray line
represents overall cumulative incidence (SPMs excluding NMSCs), the dashed
line represents solid tumors (SPMs excluding NMSCs), and the dotted line
represents t-MDS/AML.DISCUSSION
Patients with MM are surviving longer with the use of
novel agents and ASCT. Approaches to further decreasing
post-ASCT relapse rates include maintenance therapy with
combinations of novel agents. Much controversy has sur-
rounded the optimal maintenance regimen and duration of
maintenance therapy. This debate intensiﬁed with the initial
reports of increased incidence of SPMs in patients receiving
lenalidomide maintenance in the CALGB100104 and
IFM2005 trials [16,17]. In addition, a pooled analysis of 9
European trials demonstrated an increased incidence of
SPMs in patients receiving lenalidomide maintenance after
melphalan therapy, as well as in patients receiving thalido-
mide after melphalan [18]. In all series, the SPMs were
a combination of solid tumors and hematologic
malignancies.
The increased incidence of SPMs in patients with MM is
a complex story and likely represents an interplay of host and
genetic factors in addition to treatment-related risks. We
have analyzed the effects of multiple host demographic,
disease, and treatment variables to determine their rele-
vance to the later development of SPMs in our cohort of 841
patients. Our cohort analysis conﬁrms that SPM remains an
issue in patients with MM, especially those aged 55 years.
Our overall cumulative incidence of 15.9% is consistent with
the ﬁndings of the German group that reported a cumulative
incidence of 15.7% at 10 years in a retrospective study of
post-ASCT SPM incidence (including NMSCs) in patients with
MM [19]. An Arkansas group also identiﬁed an association
between older age (65 years) and SPM onset [20]. The high
rate of SPMs in our cohort likely reﬂects the combined ex-
pected increase in malignancy in older adults in the general
population, as well as the increased risk of malignancy in
patients with MM. However, these data must be considered
in the context of the increased survival of patients with MM
owing to more effective therapies. The overall survival rate
at 5 years was 60% in our entire cohort and 58% in patients
aged 55 years.
Host characteristics beyond age may also play roles in the
risk of developing SPMs. Analysis of our cohort identiﬁed
race/ethnicity as a risk factor, with a higher incidence in non-
Hispanic white patients. Slightly more than half (52%) of the
SPMs in our cohort were skin cancers, which typically are
more prevalent in non-Hispanic whites. We analyzed the
incidence of SPMs with both the inclusion and the exclusion
of NMSCs, because, of the 4 major studies analyzing SPM
outcomes after lenalidomide or thalidomide maintenance
therapy reported in 2012, 2 included NMSCs [6,20] and 2
excluded NMSCs [7,8]. Given our institution’s location in
southern California, where the population has relatively high
sun exposure, we felt it important to include all skin cancers.
We also considered previous chemotherapy exposures, given
that several drug classes have been implicated in t-MDS/
AML. Cyclophosphamide and busulfan as part of pre-ASCT
therapy, cyclophosphamide mobilization therapy, and epi-
podophyllotoxin therapy did not attain statistical signiﬁ-
cance as risk factors in our analysis; however, a previous
study reported such associations with alkylator therapy in
patients with MM [21]. The risks are likely related in part to
dosage and to duration of exposure [22], and the lack of
association in the present study may be linked in part to the
shorter-term and lower-dose alkylators used in more
modern regimens.
Immunomodulatory agents in modern regimens have
been combined with alkylators as the backbone of therapy or
Table 2
Cohort Multivariate Analysis of Risk Factors Associated with SPMs
Characteristic Including NMSCs Excluding NMSCs
Cohort/SPMs, n HR (95% CI) P Value Cohort/SPMs, n HR (95% CI) P Value
Number of patients 841/60 841/42
Sex
Female 330/17 1.0 330/12 1.0
Male 511/43 1.44 (0.82-2.53) .21 511/30 1.42 (0.72-0.78) .31
Race/ethnicity
Other 1.0 330/11 1.0
Non-Hispanic Caucasian 511/49 2.37 (1.22-4.61) .01 511/31 1.53 (0.76-0.09) .16
Age at diagnosis of MM
<55 years 408/24 1.0 408/21 1.0
55 years 433/36 2.32 (1.30-4.14) .004 433/21 1.64 (0.84-0.23) .15
Year of ASCT
1989-1999 133/22 1.0 133/18 1.0
2000-2004 278/22 0.65 (0.33-1.25) .20 278/15 0.58 (0.27-0.25) .17
2005-2009 430/16 0.56 (0.26-1.22) .14 430/9 0.42 (0.17-0.07) .07
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regarding this class of agents as risk factors for SPMs ﬁrst
arose in studies of patients treated with lenalidomide as
maintenance therapy post-ASCT. Interestingly, in those
studies, the SPMs included both hematologic malignancies
and solid tumors. Our cohort contained too few patients
receiving lenalidomide therapy either before or after ASCT toTable 3
Demographic and Therapeutic Exposure in Cases and Controls
Characteristics Including NMSCs
Cases, n (%) Controls, n (%)
Number of patients 60 60
Sex
Female 17 (28) 26 (43)
Male 43 (72) 34 (57)
Race/ethnicity
Others 11 (18) 22 (37)
Non-Hispanic Caucasian 49 (82) 38 (63)
Age at diagnosis of MM
<55 years 24 (40) 38 (63)
55 years 36 (60) 22 (37)
Pre-ASCT exposure
Irradiation 20 (33) 17 (28)
Cyclophosphamide 7 (12) 12 (20)
Doxorubicin 42 (70) 47 (78)
Etoposide 7 (12) 5 (8)
Prednisone 19 (32) 15 (25)
Thalidomide 22 (37) 19 (32)
Vincristine 40 (67) 48 (80)
Priming agents*
Cyclophosphamide 40 (70) 38 (69)
Paclitaxel 9 (16) 12 (22)
Conditioning agentsy
Total-body irradiation 9 (16) 10 (18)
Busulfan 16 (29) 18 (33)
Cyclophosphamide 19 (35) 22 (40)
Etoposide 3 (5) 4 (7)
Melphalan 50 (90) 49 (89)
Post-ASCT exposure
Dexamethazone 19 (35) 14 (25)
Interferon-a 18 (33) 16 (29)
Prednisone 5 (10) 3 (5)
Thalidomide 30 (50) 26 (47)
Timing of thalidomide exposure
None 21 (35) 26 (44)
Pre-ASCT 9 (15) 8 (13)
Post-ASCT 17 (28) 15 (25)
Both pre- and post-ASCT 13 (22) 11 (18)
Either pre- or post-ASCT 39 (65) 34 (56)
* Includes 3 cases and 5 controls without information on priming agents.
y Includes 5 cases and 5 controls without information on conditioning.meaningfully examine this exposure, but thalidomide
exposure was common. Thus, we included thalidomide
exposure in the case-control analysis, which revealed
a nonsigniﬁcant trend toward increased risk with thalido-
mide use both before and after ASCT. The large European trial
series reviewed by Palumbo et al. [18] demonstrated an
annual incidence of SPMs of approximately 1% in theExcluding NMSCs
P Value Cases, n (%) Controls, n (%) P Value
42 42
12 (29) 18 (43)
.09 30 (71) 24 (57) .19
11 (26) 16 (38)
.02 31 (74) 26 (62) .15
21 (50) 27 (64)
.01 21 (50) 15 (36) .14
.51 14 (33) 12 (29) .59
.23 6 (14) 9 (21) .41
.18 32 (76) 34 (81) .53
.48 6 (14) 3 (7) .27
.40 15 (36) 14 (33) .81
.29 14 (33) 11 (26) .27
.04 30 (71) 35 (83) .12
1.00 23 (59) 25 (66) .18
.37 6 (15) 10 (26) .14
.74 7 (18) 9 (24) .42
.53 10 (26) 11 (29) .71
.37 13 (34) 15 (39) .48
.57 3 (8) 4 (11) .57
.57 34 (89) 33 (87) .57
.28 12 (35) 10 (25) .59
.59 12 (33) 12 (29) 1.00
.42 5 (10) 3 (5) .42
.29 19 (50) 18 (47) .74
16 (38) 19 (45)
.19 7 (17) 5 (12) .17
.15 12 (28) 12 (29) .42
.12 7 (17) 6 (14) .26
.12 26 (62) 23 (55) .27
Table 4
Case-Control Multivariate Analysis of Risk Factors Associated with SPMs
Including NMSCs Excluding NMSCs
Cases/Controls, n OR (95% CI) P Value Cases/Controls, n OR (95% CI) P Value
Number of patients 60/60 42/42
Sex*
Female 17/26 1.0 12/18 1.0
Male 43/34 1.55 (0.63-3.84) .34 30/24 1.76 (0.60-5.12) .30
Race/ethnicity*
Other 11/22 1.0 11/16 1.0
Non-Hispanic Caucasian 49/38 2.90 (0.76-11.13) .12 21/26 1.82 0.41-8.13) .44
Age at diagnosis of MM*
<55 years 24/38 1.0 21/27 1.0
55 years 36/22 3.14 (1.15-8.57) .03 21/15 2.43 (0.75-7.85) .14
Timing of thalidomide exposure*
None 21/26 1.0 16/19 1.0
Pre-ASCT 9/8 4.70 (0.50-44.30) .18 7/5 8.55 (0.38-190) .18
Post-ASCT 17/15 3.31 (0.54-20.30) .20 12/12 2.29 (0.34-15.5) .39
Both pre- and post-ASCT 13/11 2.63 (0.30-22.75) .38 7/6 1.71 (0.12-24.2) .69
Any thalidomide exposurey
None 21/26 1.0 16/19 1.0
Either pre- or post-ASCT 39/34 3.48 (0.62-19.40) .15 26/23 2.59 (0.42-15.9) .30
* All of the variables were included in the multivariate conditional logistic regression model.
y ORs obtained from a multivariate conditional logistic regression model including sex, race/ethnicity, and age at diagnosis of MM.
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association between thalidomide exposure and SPMs did not
reach statistical signiﬁcance in our cohort, the trend that we
observed has potential implications. It raises the question of
whether the risk of SPMs with immunomodulatory therapy
has more to do with the immunomodulatory class of drugs
than with lenalidomide speciﬁcally.
In conclusion, our ﬁndings in this large, single-institution
series conﬁrm that the risk of SPMs remains a concern after
ASCT for MM. We were able to identify patients at greater
risk for SPMs based on age and race/ethnicity. Previously
identiﬁed risk factors for SPMs include lenalidomide therapy,
low CD34þ cell dose, chemotherapy with alkylators and
epipodophyllotoxins, and radiation exposure. Lenalidomide
has known effects on the bone marrow microenvironment,
as evidenced by poor stem cell mobilization with long-term
lenalidomide exposure. In turn, low CD34þ stem cell yields
have been associated with t-MDS/AML. However, our cohort
included few cases of lenalidomide exposure, and all cases of
t-MDS/AML occurred prior to the year 2000, before the use of
lenalidomide became widespread. The trend in our case-
control analysis toward an association between thalido-
mide exposure and post-ASCT SPMs in patients with MM
may point to a class effect rather than a lenalidomide-
speciﬁc effect. This potential class effect is consistent with
data showing similar but slightly lower rates of SPMs in
thalidomide-exposed patients compared with lenalidomide-
exposed patients [20]; however, the possible mechanism of
action remains unclear, especially because thalidomide does
not affect stem cell yields. As we enter an era of personalized
medicine in the treatment of MM in the context of improved
survival with novel drugs, the risks and beneﬁts of exposure
to these drugs must be weighed. Ultimately, we envision the
development of an algorithm incorporating host factors,
disease-related factors, and SPM risk factors to better tailor
therapy for patients with multiple myeloma.
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